| Dr David Leo Renaud, DDS | |
|
1235 Wampanoag Trl, Riverside, RI 02915-1231 | |
| (401) 437-3320 | |
| (401) 433-1537 |
| Full Name | Dr David Leo Renaud |
|---|---|
| Gender | Male |
| Speciality | Dentist - General Practice |
| Location | 1235 Wampanoag Trl, Riverside, Rhode Island |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1306999578 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 1223G0001X | Dentist - General Practice | 2357 (Rhode Island) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Dr David Leo Renaud, DDS 1235 Wampanoag Trl, Riverside, RI 02915-1231 Ph: (401) 437-3320 | Dr David Leo Renaud, DDS 1235 Wampanoag Trl, Riverside, RI 02915-1231 Ph: (401) 437-3320 |
News Archive
Determining who is the biological father of a child is a sensitive subject, but the answer can be crucial in important issues.
In the first days of their lives, French infants already cry in a different way to German babies. This was the result of a study by researchers from the Max Planck Institute for Human Cognitive and Brain Sciences in Leipzig, the Centre for Pre-language Development and Developmental Disorders (ZVES) at the University Clinic W-rzburg, and the Laboratory of Cognitive Sciences and Linguistics at the Ecole Normale Sup-rieure in Paris.
Combining two different types of treatment for migraine results in better symptom relief than taking either one of the medications, according to a study in the April 4 issue of JAMA.
NexMed, Inc, a specialty CRO with a pipeline of products based on the NexACT® technology, today announced that the Company has filed an Investigational New Drug (IND) application with the U.S. Food & Drug Administration (FDA) for a Phase II trial of its recently acquired cancer drug candidate PrevOnco™, in combination with doxorubicin in patients with advanced, unresectable hepatocellular carcinoma (HCC). The FDA has 30 days to comment on the IND before NexMed can proceed with human testing.
Bisphosphonates are a medication that has been administered since the 1990s, which reduces the overall risk of brittleness and incidence of osteoporosis. Bisphosphonates deactivate those cells used to break down bone and therefore prevent fractures caused by brittleness of the bone.
› Verified 8 days ago
Dr. John J Darby, DDS Dentist Medicare: Not Enrolled in Medicare Practice Location: 250 Wampanoag Trl, Suite 103, Riverside, RI 02915 Phone: 401-434-4413 Fax: 401-434-1187 | |
Dr. Paul E Appelbaum, DMD Dentist Medicare: Medicare Enrolled Practice Location: 1445 Wampanoag Trl, Riverside, RI 02915 Phone: 401-433-2400 Fax: 401-433-2403 | |
Robin M Rawlinson, D.M.D. Dentist Medicare: Medicare Enrolled Practice Location: 2861 Pawtucket Ave, Riverside, RI 02915 Phone: 401-434-1334 | |
Gian Calandrelli, DMD Dentist Medicare: Not Enrolled in Medicare Practice Location: 250 Wampanoag Trl Ste 103, Riverside, RI 02915 Phone: 401-273-6780 | |
Kenneth J Rawlinson, D.D.S. Dentist Medicare: Medicare Enrolled Practice Location: 2861 Pawtucket Ave, Riverside, RI 02915 Phone: 401-434-1334 | |
Dr. Stephen S. Cary, DMD Dentist Medicare: Not Enrolled in Medicare Practice Location: 600 Wampanoag Trl, Riverside, RI 02915 Phone: 401-431-2180 Fax: 401-435-3644 |